DNA construction firm Gen9 and British synthetic biology network SynbiCite have announced a partnership to increase access to gene synthesis technology.

Under the terms of the agreement, SynbiCite members will have access to Gen9's BioFab high-throughput gene synthesis platform. Financial and other details of the agreement were not disclosed.

"Gen9's DNA synthesis technologies will be an invaluable resource to our members," John Collins, SynbiCite's commercial director, said in a statement. "These types of industry partnerships enable faster commercialization of breakthrough technologies in the space."

Cambridge, Massachusetts-based Gen9 said in a statement that it offers high-quality, low-cost DNA constructs on large scales.

The deal is Gen9's latest to promote its DNA synthesis platform. Last fall, the firmsigned a partnership with digital lab notebook maker Benchling on an integrated DNA library design feature, and it inked a deal to provide DNA parts to the International Genetically Engineered Machine Competition.